There hasn't been a significant rise in Astrazeneca, despite the approval of the vaccine in the UK, the orders from Indonesia and Taiwan and reassuring news about the effectiveness of the vaccine. I think some negative publicity about the vaccine effectiveness in comparison to the other vaccines in the US could have led to this consolidation, but even if the other vaccines are a few percents more efficient, the cost and storage efficiency will be a large differentiator for many countries. The approval of the UK will give confidence to other countries (India, Brazil, Europe,...) to speed up the approval process, I expect this will cause the stock to break upwards after more countries approve it.
Komen:
Astrazeneca broke out today, looking bullish